XTalks

JUNE 20, 2022

Alnylam’s Onpattro was its first licensed and approved RNAi therapy for ATTR polyneuropathy. Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

SEPTEMBER 2, 2020

Jounce could also receive up to $685 million in future clinical, regulatory and commercial milestone payments, as well as royalties ranging from high single digit to mid-teens based upon worldwide sales, subject to certain adjustments. The post Gilead licenses Jounce immunotherapy for $800m appeared first on.

Licensing 66

Licensing Licensing Antibody Immune Response 66

Pharmaceutical Technology

JUNE 21, 2023

Hemgenix works by dosing a patient with an engineered adeno-associated virus (AAV), containing the gene responsible for producing a protein called factor IX. This protein helps to form blood clots and stop bleeding, with haemophilia B arising when the body is partially or completely unable to produce it.

Gene Therapy 246

Gene Therapy Gene Protein Sales 246

pharmaphorum

DECEMBER 7, 2021

billion in milestones depending on sales levels if the antisense-based drug reaches the market. The post AZ gets closer to Ionis, licensing amyloidosis drug in $3.6bn deal appeared first on. The deal is another sizeable one too, with an upfront fee of $200 million, another $485 million tied to regulatory approvals, and up to $2.9

Licensing 59

Licensing Licensing Drugs Marketing 59

Pharmaceutical Technology

JULY 1, 2022

Twist's VHH libraries, used for discovering and developing antibodies for use in immuno-oncology, will be licensed by Ildong for three years for research and development works. . This VHH library licensing agreement with Ildong is our first collaboration with a South Korea-based company and broadens our presence in the Asia-Pacific region.”.

Antibody 147

Antibody Development Licensing Licensing 147

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

Pharmaceutical Technology

MARCH 23, 2023

Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements.

Licensing 147

Licensing Licensing Sales Trials 147

The Pharma Data

JUNE 14, 2023

Cedilla’s small molecules conditionally modulate the protein complex in its functional state resulting in highly selective inhibition. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG. billion euros.

Licensing 40

Licensing Licensing Life Science Development 40

XTalks

JANUARY 4, 2024

Hemophilia B, also known as congenital Factor IX (FIX) deficiency or Christmas disease, is a rare genetic bleeding disorder caused by a deficiency or defect in the FIX clotting protein. Treatment involves replacing the missing FIX clotting protein, traditionally through regular infusions. Priced at $3.5

Gene Therapy 109

Gene Therapy Gene Gene Editing Sales 109

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. The pharma will also pay tiered royalties on commercial net sales of the antibody.

Antibody 98

Antibody Trials Licensing Licensing 98

The Pharma Data

DECEMBER 13, 2020

. Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and $695 million in additional potential milestones, plus royalties on global net product sales. sales and up to $410 million in additional ex-U.S. CAMBRIDGE, Mass.,

Licensing 40

Licensing Licensing Clinical Trials Clinical Trials 40

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) hold the number 2 and number 11 spots, respectively, in annual sales of the top oncology products. Herceptin (Trastuzumab) and Mabthera (Rituximab).

Clinical Trials 90

Clinical Trials Clinical Trials Production Trials 90

pharmaphorum

DECEMBER 2, 2021

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. billion if the drug reaches the market and hits sales objectives.

Antibody 108

Antibody Licensing Licensing Gene Therapy 108

pharmaphorum

JANUARY 13, 2022

Sanofi has joined a growing list of drugmakers going after alpha-synuclein targeting drugs for Parkinson’s disease, licensing a bispecific antibody from South Korea’s ABL Bio in a deal that could be worth more than $1 billion. The post Sanofi places $75m bet with ABL on popular Parkinson’s drug target appeared first on.

Antibody 95

Antibody Drugs Protein Licensing 95

XTalks

APRIL 3, 2024

The RBCs in circulation are marked by proteins in the complement system for removal by the spleen and liver. billion in sales in 2023, Ultomiris was approved in 2018 and generated $3 billion in revenue last year. In 2023, its second year on the market, the drug earned $91 million in sales.

FDA Approval 85

FDA Approval Sales Trials Development 85

pharmaphorum

MARCH 31, 2021

Novartis has added to its pipeline of radiopharmaceuticals pipeline once again, licensing a series of agents from iTheranostics that can be used to show where tumours are located in the body. . Novartis licenses the drug from Genmab and reformulated into its Sensoready autoinjector pen. billion or more in peak sales.

Licensing 98

Licensing Licensing Gene Therapy Sales 98

The Pharma Data

AUGUST 17, 2020

. (“Dragonfly”), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. Dragonfly received U.S.

Licensing 52

Licensing Licensing Development Production 52

Roots Analysis

FEBRUARY 26, 2024

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development. You can also download the SAMPLE REPORT on subcutaneous medications by Roots Analysis.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

pharmaphorum

JUNE 4, 2021

Bayer has agreed to buy Noria Therapeutics and its subsidiary PSMA Therapeutics, adding to its pipeline of radionuclide drugs for cancer as sales of its lead product in the category – Xofigo – continue to decline. . The technology behind the drug was licensed from Weill Cornell Medicine and Johns Hopkins University in the US.

Antibody 63

Antibody Licensing Licensing Protein 63

pharmaphorum

MARCH 19, 2021

Now the Ireland-based firm said that early data from studies shows the system can detect and identify the COVID virus S-Protein in quantities at 40 femtograms per millilitre at close to 100% specificity. It has licensed in a patented breathalyser, the analysts noted. A femtogram is 0.000000000000000001 kilograms.

Contamination 145

Contamination Clinical Trials Clinical Trials Protein 145

pharmaphorum

MAY 31, 2022

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million upfront to license the vaccine in 2017, clearing the way for GSK’s acquisition. billion in sales last year. billion in sales last year.

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

pharmaphorum

DECEMBER 22, 2020

The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders. million on the table if certain development, regulatory and sales goals are achieved. This deal involves an upfront payment of $7 million but there is up to $154.5

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

AUGUST 10, 2020

Novavax is partnering up with the Serum Institute of India Private Limited (SIIPL) in a licensing deal to development and marketing of up to one billion doses of its potential recombinant COVID-19 vaccine candidate, NVX?CoV2373. The candidate is built upon a stable, prefusion protein and includes Novavax’s Matrix?M M adjuvant.

Vaccination 52

Vaccination Vaccine Licensing Licensing 52

pharmaphorum

JUNE 20, 2022

The deal gives Valneva a cash injection that it will be able to use to advance Lyme disease candidate VLA15 towards the market, but the revised licensing terms means that the French biotech will shoulder more of the financial cost of the development programme.

Vaccination 97

Vaccination Vaccine Licensing Licensing 97

pharmaphorum

SEPTEMBER 30, 2022

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases associated with inflammation.

Drugs 59

Drugs Licensing Licensing Protein 59

pharmaphorum

OCTOBER 19, 2022

(a Zymeworks subsidiary) have entered into a licensing agreement, under which Jazz is to acquire the exclusive development and commercialisation rights to Zymeworks’ zanidatamab across all indications in the US, Europe, Japan, and all other territories – except for those Asia Pacific territories previously licensed by Zymeworks.

Licensing 40

Licensing Licensing Sales Antibody 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Alkaloids, natural dyes, drugs, proteins, and enzymes are some of the important classes of natural heterocyclic compounds essential for human life. The most common heteroatoms are nitrogen (N), oxygen (O) and sulphur (S). Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects.

Antibody 130

Antibody Hormones DNA Licensing 130

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. The antibody targets a specific conserved region of the SARS-CoV-2 spike protein. Kate Krav-Rude/Shutterstock. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

The Pharma Data

NOVEMBER 17, 2020

Lead Pharma has entered into a collaboration and license agreement with Roche , hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases. . Source link.

Immune Response 52

Immune Response Licensing Licensing Sales 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). GPCR – G protein-coupled receptors. . TOKYO and CAMBRIDGE, England , Dec.

Licensing 40

Licensing Licensing Production Development 40

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. Under the agreement, Boehringer Ingelheim has the option to license dark antigens discovered and validated by Enara Bio.

Genomics 62

Genomics Genome Licensing Licensing 62

The Pharma Data

JANUARY 5, 2021

Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is because many proteins do not have small-molecule binding sites. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Protein Bioavailability DNA 52

pharmaphorum

OCTOBER 29, 2020

The Swiss pharma group already sells one gene therapy for inherited retinal diseases (IRDs) – Luxturna (voretigene neparvovec) – for which it licensed ex-US rights from Spark Therapeutics (now part of Roche) in 2018. Novartis’ big move in the gene therapy market came when it bought AveXis for $8.7

Gene Therapy 40

Gene Therapy Gene Gene Silencing Protein 40

pharmaphorum

MAY 30, 2022

At the end of the study 18 of them (86%) had an immunological response to the shots, which is intended to treat or prevent metastasis by stimulating a T cell response to a protein called RhoC that has been implicated in tumour spread.

Vaccination 72

Vaccination Vaccine Trials Licensing 72

pharmaphorum

APRIL 7, 2021

In its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 Last week, it licensed a series of fibroblast activation protein (FAP) targeting agents from iTheranostics that can be used to image and potentially to treat tumours. The drug made $445 million in sales last year.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

JANUARY 12, 2021

Boehringer Ingelheim has announced it has signed a collaboration and licensing deal with Enara Bio to advance novel targeted cancer immunotherapies. Dark Antigens are in reference to a newer class of cancer antigens derived from a portion of the human genome not normally expressed as a protein. Michael Vi/Shutterstock.

Research 52

Research Genomics Genome Licensing 52